Conditions: Parkinson's Disease
Keywords: attention mild cognitive impairment dementia
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 9
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine the relationship between attention and quality of life and how rivastigmine and atomoxetine alter attention in non-demented persons with Parkinson's disease (PD).

Detailed description:
Cognitive dysfunction can occur in early stage of Parkinson's disease (PD) and increases as PD progresses. Attention deficits in PD patients with dementia strongly predict the impairment of their daily living activities.

Previous studies have shown that atomoxetine improves PD executive dysfunction and rivastigmine improves attention deficits in PD patients with dementia without worsening the motor symptoms.

The aim of this study is to examine the effect of atomoxetine and rivastigmine on attention and quality of life in PD patients without disabling cognitive impairment.

Arms:
arm 1: Strattera 10-30 mg b.i.d. arm 2: Exelon 1.5-4.5 mg b.i.d. arm 3: sugar pill

Interventions: intervention 1: Strattera intervention 2: Exelon intervention 3: Placebo
Intervention descriptions: intervention 1: 10-30 mg b.i.d. for 6 weeks intervention 2: 1.5-4.5 mg b.i.d. for 6 weeks intervention 3: 2-6 pills for 6 weeks

Protocol document: